|
|
News Breaks | | | | October 15, 2012 | | 08:31 EDT |  | SRPT | Sarepta DMD drug clearly active, says Piper Jaffray
After Dr. Jerry Mendell presented the Phase IIb data on Sarepta's Eteplirsen at the World Muscle Society Congress over the weekend, Piper Jaffray says the Duchenne Muscular Dystrophy, or DMD, treatment is clearly active. The firm sees potential for acclerated approval and reiterates an Overweight rating on Sarepta with a $38 price target. | |
|
News For SRPT From The Last 14 Days Check below for free stories on SRPT the last two weeks. |
|
|
| May 21, 2013 | | 07:34 EDT |  | SRPT | UBS to host a conference
 Subscribe for More Information | | | May 16, 2013 | | 07:29 EDT | | SRPT | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. | | | May 9, 2013 | | 12:21 EDT |  | SRPT | Sarepta climbs after saying documents to be submitted this month
Subscribe for More Information | | | 07:29 EDT |  | SRPT | Sarepta reports Q1 EPS (41c), consensus (62c)
Reports Q1 revenue $4.5M, consensus $5.85M. | |
|
|
|
|
|
|
